AL01 Estimating the Probability of Reported Versus Theoretical Drug-Drug Interactions in Headaches Medicine
V. Kaytser, I. Hakkinen, P. Zhang
Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, United States
Correspondence: V. Kaytser; I. Hakkinen; P. Zhang
Background: This project aims to compare the likelihood of a theoretical drug-drug interaction between a number of abortives and preventives using DrugBank"s application programing interface (API) versus the empirically reported interactions using the FDA"s Adverse Event Reporting System (FAERS) API.
Methods: We included, as input, abortive and preventive drugs from the AHS Position Statement on Integrating New Migraine Treatments into Clinical Practice, as well as Szperka"s, Migraine Care in the Era of COVID-19. All combinations of up to 3 abortives and/or preventives are screened for interactions through DrugBank and FAERS. If at least one interaction, of any type, is listed, then it is included here and compared across the two databases.
Results: We included 38 abortives and 23 preventives. We downloaded DrugBank data on August 26, 2020 and included FAERS data from October 2012 to March 2020. Table 1 contains the number of interactions for a given number of medications. Due to hardware limitations, 3 abortives vs. 3 preventives was not analyzed.
Conclusion: The likelihood of an interaction increases as the number of combinations of abortives and preventives increases. Per DrugBank, the chance of an interaction is >99% once more than 3 drugs are used in combination. Whereas, the reported interaction is actually less, 60%, per FAERS. This data may help providers to use more rational polypharmacy.